BIO-TECHNE Corp
Close on Oct 19, 2026
- Market cap
- $11.40B
- P/E (TTM)
- 62.5
- Dividend yield
- 0.44%
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | Before market open | $321.20M | $0.35 | $0.52 |
| Q3 FY2026 Ended Mar 31, 2026 | May 6, 2026 | Before market open | $311.40M | $0.32 | $0.53 |
| Q2 FY2026 Ended Dec 31, 2025 | Feb 4, 2026 | Before market open | $295.90M | $0.24 | $0.46 |
| Q1 FY2026 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | $286.60M | $0.24 | $0.42 |
| Q4 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | $317.00M | $-0.11 | $0.53 |
| Q3 FY2025 Ended Mar 31, 2025 | May 7, 2025 | Before market open | $316.20M | $0.14 | $0.56 |
| Q2 FY2025 Ended Dec 31, 2024 | Feb 5, 2025 | Before market open | $297.00M | $0.22 | $0.42 |
| Q1 FY2025 Ended Sep 30, 2024 | Oct 30, 2024 | Before market open | $289.50M | $0.21 | $0.42 |
| Q4 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | Before market open | – | – | – |
| Q3 FY2024 Ended Mar 31, 2024 | May 1, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Dec 31, 2023 | Feb 1, 2024 | Before market open | – | – | – |
Press releases
Announcements Bio-Techne filed with the SEC
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Techne Releases Fourth Quarter Fiscal 2026 Results
Results of operations · Other events · EX-99.1 to Form 8-K
David Clair, Vice President , Investor Relations
Results of operations · Other events · EX-99.2 to Form 8-K
JOINT PRESS RELEASE, DATED JUNE 25, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Techne Releases Third Quarter Fiscal 2026 Results
Results of operations · Other events · EX-99.1 to Form 8-K
David Clair, Vice President , Investor Relations
Results of operations · Other events · EX-99.2 to Form 8-K
Bio-Techne Announces Changes to its Leadership Team
Executive or director change · Other events · EX-99.1 to Form 8-K
Bio-Techne Releases Second Quarter Fiscal 2026 Results
Results of operations · Other events · EX-99.1 to Form 8-K
David Clair, Vice President , Investor Relations
Results of operations · Other events · EX-99.2 to Form 8-K
Bio-Techne Releases First Quarter Fiscal 2026 Results
Results of operations · Shareholder vote results · Other events · EX-99.1 to Form 8-K
David Clair, Vice President , Investor Relations & Corporate Development
Results of operations · Shareholder vote results · Other events · EX-99.2 to Form 8-K
Bio-Techne Releases Fourth Quarter Fiscal 2025 Results
Results of operations · Other events · EX-99.1 to Form 8-K
David Clair, Vice President , Investor Relations & Corporate Development
Results of operations · Other events · EX-99.2 to Form 8-K
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS
Results of operations · Other events · EX-99.1 to Form 8-K
BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM
Results of operations · Other events · EX-99.2 to Form 8-K
BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2025 RESULTS
Results of operations · Executive or director change · Other events · EX-99.1 to Form 8-K
David Clair, Vice President , Investor Relations & Corporate Development
Results of operations · Executive or director change · Other events · EX-99.2 to Form 8-K
Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors
Results of operations · Executive or director change · Other events · EX-99.3 to Form 8-K
BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS
Results of operations · Shareholder vote results · Other events · EX-99.EX-99_1 to Form 8-K
David Clair, Vice President , Investor Relations & Corporate Development
Results of operations · Shareholder vote results · Other events · EX-99.EX-99_2 to Form 8-K
BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2024 RESULTS
Results of operations · Other events · EX-99.1 to Form 8-K
David Clair, Vice President , Investor Relations & Corporate Development
Results of operations · Other events · EX-99.2 to Form 8-K
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2024 RESULTS
Results of operations · Other events · EX-99.1 to Form 8-K
David Clair, Vice President , Investor Relations & Corporate Development
Results of operations · Other events · EX-99.2 to Form 8-K
BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS
Executive or director change · Other events · EX-99.1 to Form 8-K
BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2024 RESULTS
Results of operations · Other events · EX-99.1 to Form 8-K
David Clair, Vice President , Investor Relations & Corporate Development
Results of operations · Other events · EX-99.2 to Form 8-K
BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT
Executive or director change · Other events · EX-99.1 to Form 8-K
BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2024 RESULTS
Results of operations · Shareholder vote results · Other events · EX-99.1 to Form 8-K
David Clair, Vice President , Investor Relations & Corporate Development
Results of operations · Shareholder vote results · Other events · EX-99.2 to Form 8-K
BIO-TECHNE APPOINTS KIM KELDERMAN AS CHIEF EXECUTIVE OFFICER
Executive or director change · Other events · EX-99.1 to Form 8-K
BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2023 RESULTS
Results of operations · Other events · EX-99.1 to Form 8-K
David Clair, Vice President , Investor Relations
Results of operations · Other events · EX-99.2 to Form 8-K